iMDx Hires Natera Sales Vet to Drive Transplant Diagnostics Launch…

Event summary

Insight Molecular Diagnostics (IMDx) appointed Donnie Purto as SVP of Sales to lead commercialization of GraftAssureDx, pending FDA approval.
Purto brings 20 years of diagnostics sales experience, including a decade at Natera leading high-revenue teams in competitive markets.
GraftAssureDx, an IVD kit for transplant rejection testing, is under FDA review with a planned 2027 launch.
IMDx has established relationships with top transplant centers, including Cleveland Clinic and Mayo Clinic, for FDA submission and future commercialization.

The big picture

IMDx’s hire of a seasoned diagnostics sales leader underscores its push to disrupt the transplant health testing market. The appointment comes as the company awaits FDA approval for GraftAssureDx, a key product in its strategy to commercialize donor-derived cell-free DNA (dd-cfDNA) technology. Success hinges on regulatory clearance and the ability to scale sales in a competitive diagnostics landscape.

What we're watching

Regulatory Timing: Whether the FDA will authorize GraftAssureDx by 2027, clearing the path for commercial launch.
Market Penetration: How quickly IMDx can convert existing transplant center relationships into revenue post-approval.
Competitive Positioning: Whether Purto’s sales strategy can establish GraftAssureDx as a market leader in transplant diagnostics.